Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex H Chang

Showing results (21-30 of 71) with videos related to

Pageof 8
Sort By:
Frontiers in Oncology|July 19, 2021
New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaLinqin Wang, Ruimin Hong, Linghui Zhou, et al.
Discover Oncology|May 20, 2026
Immune microenvironment and its influence on CAR-T treatment outcomes in B-NHLDanyang Li, Zhonghua Fu, Rui Liu, et al.
NPJ Precision Oncology|April 10, 2026
CD22-targeted immunotherapy for B-cell acute lymphoblastic leukemia progressing following CD19-targeted immunotherapyFengmei Song, Junfang Yang, Mingming Zhang, et al.
Frontiers in Immunology|October 16, 2023
Demethylating agents in combination with CD7-targeted CAR-T for the successful treatment of a case with mixed-phenotype acute leukemia relapsed after allogeneic hematopoietic stem cell transplantation: A Case ReportYing Han, Hao Yao, Guang-Cui He, et al.
Blood Science (Baltimore, Md.)|March 16, 2026
Zanubrutinib enhances CD19 CAR T killing of B-cell lymphoma by inhibiting BTK phosphorylation, regulating PI3K/AKT/mTOR pathway, and promoting autophagyHao Yao, Ling Qiu, Shi-Hui Ren, et al.
Frontiers in Immunology|May 28, 2024
Case report: Donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remissionXiaojuan Miao, Yanrong Shuai, Ying Han, et al.
Frontiers in Oncology|October 18, 2021
Corrigendum: Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHLYuan Meng, Biping Deng, Luan Rong, et al.
International Journal of Hematology|September 10, 2025
Sequential intrathoracic injection and intravenous infusion of BCMA CAR-T cells in a patient with relapsed/refractory primary plasma cell leukemiaWei Han, Shuyang Wang, Mingming Zhang, et al.
Experimental Hematology & Oncology|March 5, 2024
Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignanciesLinqin Wang, Yuqi Lv, Linghui Zhou, et al.
Frontiers in Oncology|November 18, 2021
Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant RelapseLijuan Ding, Yiyun Wang, Ruimin Hong, et al.
Pageof 8

Showing results (21-30 of 71) with videos related to

Sort By:
Pageof 8
Frontiers in Oncology|July 19, 2021
New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaLinqin Wang, Ruimin Hong, Linghui Zhou, et al.
Discover Oncology|May 20, 2026
Immune microenvironment and its influence on CAR-T treatment outcomes in B-NHLDanyang Li, Zhonghua Fu, Rui Liu, et al.
NPJ Precision Oncology|April 10, 2026
CD22-targeted immunotherapy for B-cell acute lymphoblastic leukemia progressing following CD19-targeted immunotherapyFengmei Song, Junfang Yang, Mingming Zhang, et al.
Frontiers in Immunology|October 16, 2023
Demethylating agents in combination with CD7-targeted CAR-T for the successful treatment of a case with mixed-phenotype acute leukemia relapsed after allogeneic hematopoietic stem cell transplantation: A Case ReportYing Han, Hao Yao, Guang-Cui He, et al.
Blood Science (Baltimore, Md.)|March 16, 2026
Zanubrutinib enhances CD19 CAR T killing of B-cell lymphoma by inhibiting BTK phosphorylation, regulating PI3K/AKT/mTOR pathway, and promoting autophagyHao Yao, Ling Qiu, Shi-Hui Ren, et al.
Frontiers in Immunology|May 28, 2024
Case report: Donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remissionXiaojuan Miao, Yanrong Shuai, Ying Han, et al.
Frontiers in Oncology|October 18, 2021
Corrigendum: Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHLYuan Meng, Biping Deng, Luan Rong, et al.
International Journal of Hematology|September 10, 2025
Sequential intrathoracic injection and intravenous infusion of BCMA CAR-T cells in a patient with relapsed/refractory primary plasma cell leukemiaWei Han, Shuyang Wang, Mingming Zhang, et al.
Experimental Hematology & Oncology|March 5, 2024
Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignanciesLinqin Wang, Yuqi Lv, Linghui Zhou, et al.
Frontiers in Oncology|November 18, 2021
Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant RelapseLijuan Ding, Yiyun Wang, Ruimin Hong, et al.
Pageof 8